Individualized Care Plans Advised for T2DM With Heart Failure

FRIDAY, June 7, 2019 -- Team-based care emphasizing development of individualized care plans is recommended for management of type 2 diabetes mellitus (T2DM) and heart failure, according to a scientific statement issued by the American Heart...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract While rates of ischemic complications in type 2 diabetes mellitus seem to be declining, some of the most feared and costly complications, namely end-stage kidney disease (ESKD), heart failure, and lower limb amputations, remain on the rise. Herein, we discuss how the results from the Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE) trial may change this calculus.1 The development of chronic kidney disease (CKD) in type 2 diabetes mellitus marks the beginning of a sharp increase in cardio-renal complications.2 Indeed, in ty...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America Abstract Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes ...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
ConclusionsThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.RésuméObjectifsLes auteurs de deux grands essais randomisés ont récemment publié leurs conclusions concernant les effets d'un agoniste du récepteur au glucagon-like peptide-1 (A-GLP-1R) (essai HARMONY) et d'un inhibiteur de la dipeptidyl peptidase 4 (DPP-4) (essai CARMELINA) sur les b&eac...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: AHA SCIENTIFIC STATEMENT Source Type: research
Authors: Donath MY, Meier DT, Böni-Schnetzler M Abstract The role of chronic inflammation in the pathogenesis of type 2 diabetes mellitus and associated complications is now well established. Therapeutic interventions counteracting metabolic inflammation improve insulin secretion and action, glucose control, and may prevent long-term complications. Thus, a number of anti-inflammatory drugs approved for the treatment of other inflammatory conditions are evaluated in patients with metabolic syndrome. Most advanced are clinical studies with interleukin-1 antagonists showing improved β-cell function and glyca...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
BACKGROUND: Cardiac and renal diseases commonly occur with bidirectional interactions. We hypothesized that cardiac and inflammatory biomarkers may assist in identification of patients with type 2 diabetes mellitus (T2DM) at high risk of worsening renal function. METHODS: In this exploratory analysis from SAVOR-TIMI 53, concentrations of high-sensitivity cardiac troponin T (hs-TnT), N-terminal pro–B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-CRP) were measured in baseline serum samples of 12310 patients. The primary end point for this analysis was a ≥40% decrease in estimate...
Source: Clinical Chemistry - Category: Chemistry Authors: Tags: Endocrinology and Metabolism Source Type: research
ABSTRACTThe ESC has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the HFA of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held in January 2019 in Frankfurt. This expert consensus report is neither a guideline update nor a position statement, but rather a summary and consensus view in the form of consensus recommendations. The report describes how these guidance statements are supported by evidence, ...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
AbstractPurpose of ReviewAt the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented.Recent FindingsThe CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD ris...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
AbstractPurpose of ReviewSince the 2008 FDA guidance restructuring the design of trials for the approval of novel glucose-lowering agents, 13 medications have now been evaluated by dedicated cardiovascular outcome trials. All of the completed trials have included data (though with varying definitions) on rates of hospitalization for heart failure. This review is aimed at summarizing current heart failure outcome data available from cardiovascular safety trials for novel glucose-lowering agents in patients with type 2 diabetes mellitus.Recent FindingsThere appears to be growing evidence for the benefit of sodium –gluc...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
ConclusionsAmong patients with T2DM after a recent ACS or AIS, treatment with vildagliptin was not associated with increased risks of CV death, nonfatal MI, nonfatal stroke, and hospitalization for HF.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research
More News: Cardiology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Pharmaceuticals